logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Merz Therapeutics acquires INBRIJA® and (F)AMPYRA® products from Acorda Therapeutics in the therapy areas of Multiple Sclerosis and Parkinson's disease worth 185 million USD

Jul 10, 2024•over 1 year ago

Acquiring Company

Merz Therapeutics

Acquired Company

Acorda Therapeutics

FrankfurtPearl RiverTherapeuticsBiotechnologyHealth CareTherapeuticsBiotechnologyHealth Care

Description

Merz Therapeutics has successfully acquired the products INBRIJA® and (F)AMPYRA® from Acorda Therapeutics, Inc. for 185 million USD. This strategic acquisition strengthens Merz Therapeutics' market position in the Parkinson and Multiple Sclerosis (MS) segments and aligns with the company's global growth strategy. The acquisition aims to expand the company's product portfolio and provide sustainable results for a broader group of people with neurological diseases.

Company Information

Company

Merz Therapeutics

Location

Frankfurt, Hesse, Germany

About

Merz Therapeutics, a business of Frankfurt-based Merz Group, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed